{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T02:04:17Z","timestamp":1783908257212,"version":"3.55.0"},"reference-count":15,"publisher":"Walter de Gruyter GmbH","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>SC2 is a low-prevalence antigen of the Scianna blood group system, historically associated with hemolytic disease of the fetus and newborn and only one prior case of hemolytic transfusion reaction (HTR). We report a second case of anti-Sc2\u2013mediated HTR in a 33-year-old woman with \u03b2-thalassemia major and a history of anti-Sc2. She presented for routine transfusion and received 1 group O, D\u2013E\u2013K\u2013S\u2013Jk(a\u2013) red blood cell (RBC) unit that was crossmatch compatible by the antihuman globulin (AHG)\u2013polyethylene glycol testing method. Shortly after the transfusion, she developed chills and back pain that resolved with meperidine. Several hours later, she experienced jaundice, dark urine, and fatigue. Laboratory evaluation revealed a hemoglobin drop below the pre-transfusion baseline, elevated bilirubin (8.0 mg\/dL, reference range \u22641.2 mg\/dL), and a 2+ incompatibility between the post-transfusion sample and the donor RBC unit segment. Although the direct antiglobulin test and the antibody screen remained negative, reference testing confirmed anti-Sc2 in the post-transfusion plasma, and the donor RBC unit was Sc2+. This case reinforces the clinical relevance of anti-Sc2, highlights limitations of conventional antibody screening and the AHG crossmatch in detecting low-prevalence antigens, and supports the need for heightened clinical suspicion and individualized transfusion strategies, including additional targeted pre-transf usion testing, early consultation with reference laboratories, and sourcing of antigen-negative units in patients with known rare alloantibodies.<\/jats:p>","DOI":"10.2478\/immunohematology-2025-019","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T13:26:47Z","timestamp":1767965207000},"page":"132-135","source":"Crossref","is-referenced-by-count":0,"title":["The second reported case of a hemolytic transfusion reaction caused by anti-Sc2: a clinical diagnosis"],"prefix":"10.2478","volume":"41","author":[{"given":"Hang Mieu","family":"Ha","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine , University of California , Davis , Sacramento, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley","family":"Rubenstein","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine , University of California , Davis , Sacramento, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Asif","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology , University of Washington , Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,12,31]]},"reference":[{"key":"2026071214322077391_j_immunohematology-2025-019_ref_001","doi-asserted-by":"crossref","unstructured":"Brunker PAR, Flegel WA. An update on the Scianna blood group system. Immunohematology 2019;35:48\u201350.","DOI":"10.21307\/immunohematology-2020-012"},{"key":"2026071214322077391_j_immunohematology-2025-019_ref_002","doi-asserted-by":"crossref","unstructured":"Floch A, Lomas-Francis C, Vege S, et al. Two new Scianna variants causing loss of high prevalence antigens: ERMAP model and 3D analysis of the antigens. Transfusion 2023;63:230\u20138. doi: 10.1111\/trf.17182.","DOI":"10.1111\/trf.17182"},{"key":"2026071214322077391_j_immunohematology-2025-019_ref_003","doi-asserted-by":"crossref","unstructured":"Srivastava K, Albasri J, Alsuhaibani OM, et al. SCAR: the high-prevalence antigen 013.008 in the Scianna blood group system. Transfusion 2021;61:246\u201354. doi: 10.1111\/trf.16152.","DOI":"10.1111\/trf.16152"},{"key":"2026071214322077391_j_immunohematology-2025-019_ref_004","doi-asserted-by":"crossref","unstructured":"Anderson C, Hunter J, Zipursky A, Lewis M, Chown B. An antibody defining a new blood group antigen, Bua. Transfusion 1963;3:30\u20133. doi: 10.1111\/j.1537-2995.1963.tb04599.x.","DOI":"10.1111\/j.1537-2995.1963.tb04599.x"},{"key":"2026071214322077391_j_immunohematology-2025-019_ref_005","doi-asserted-by":"crossref","unstructured":"Schmidt RP, Griffitts JJ, Northman FF. A new antibody, anti-Sm, reacting with a high incidence antigen. Transfusion 1962;2:338\u201340. doi: 10.1111\/j.1537-2995.1962.tb00250.x.","DOI":"10.1111\/j.1537-2995.1962.tb00250.x"},{"key":"2026071214322077391_j_immunohematology-2025-019_ref_006","doi-asserted-by":"crossref","unstructured":"Daniels G. Scianna blood group system. In: Human blood groups. John Wiley & Sons, Hoboken, NJ, 2013:371\u20135. doi: 10.1002\/9781118493595.ch13.","DOI":"10.1002\/9781118493595.ch13"},{"key":"2026071214322077391_j_immunohematology-2025-019_ref_007","doi-asserted-by":"crossref","unstructured":"DeMarco M, Uhl L, Fields L, Pacini D, Gorlin JB, Kruskall MS. Hemolytic disease of the newborn due to the Scianna antibody, anti-Sc2. Transfusion 1995;35:58\u201360. doi: 10.1046\/j.1537-2995.1995.35195090664.x.","DOI":"10.1046\/j.1537-2995.1995.35195090664.x"},{"key":"2026071214322077391_j_immunohematology-2025-019_ref_008","doi-asserted-by":"crossref","unstructured":"N\u00fa\u00f1ez Ahumada MA, Arancibia Aros CE, Villalobos Pavez CE, et al. A mild case of hemolytic disease of the fetus and newborn due to anti-Sc2. Immunohematology 2021;37:122\u20135. doi: 10.21307\/immunohematology-2021-018.","DOI":"10.21307\/immunohematology-2021-018"},{"key":"2026071214322077391_j_immunohematology-2025-019_ref_009","doi-asserted-by":"crossref","unstructured":"Lemay AS, Tong TN, Branch DR, et al. The first case of severe acute hemolytic transfusion reaction caused by anti-Sc2. Transfusion 2018;58:2506\u201312. doi: 10.1111\/trf.14867.","DOI":"10.1111\/trf.14867"},{"key":"2026071214322077391_j_immunohematology-2025-019_ref_010","doi-asserted-by":"crossref","unstructured":"Reid ME, Lomas-Francis C, Olsson ML. The blood group antigen factsbook. 3rd ed. Academic Press, San Diego, CA, 2012.","DOI":"10.1016\/B978-0-12-415849-8.00001-6"},{"key":"2026071214322077391_j_immunohematology-2025-019_ref_011","doi-asserted-by":"crossref","unstructured":"Panch SR, Montemayor-Garcia C, K lein HG. Hemolytic transfusion reactions. N Engl J Med 2019;381:150\u201362. doi: 10.1056\/NEJMra1802338.","DOI":"10.1056\/NEJMra1802338"},{"key":"2026071214322077391_j_immunohematology-2025-019_ref_012","unstructured":"Alvarez A, Rives S, Montoto S, Sanz C, Pereira A. Relative sensitivity of direct antiglobulin test, antibody\u2019s elution and flow cytometry in the serologic diagnosis of immune hemolytic transfusion reactions. Haematologica 2000;85:186\u20138."},{"key":"2026071214322077391_j_immunohematology-2025-019_ref_013","doi-asserted-by":"crossref","unstructured":"Zanetti RC, Vasta LM, Romanelli K, Newton TC. Management of hyperhemolysis in \u03b2-thalassemia with multiple immunosuppressives, including complement blockade. J Pediatr Hematol Oncol 2021;43:e1145\u20137. doi: 10.1097\/MPH. 0000000000002059.","DOI":"10.1097\/MPH.0000000000002059"},{"key":"2026071214322077391_j_immunohematology-2025-019_ref_014","doi-asserted-by":"crossref","unstructured":"Kasinathan G, Sathar J. Post-transfusion hyperhemolysis syndrome in a patient with beta thalassemia major. Clin Case Rep 2021;9:e04226. doi: 10.1002\/ccr3.4226.","DOI":"10.1002\/ccr3.4226"},{"key":"2026071214322077391_j_immunohematology-2025-019_ref_015","doi-asserted-by":"crossref","unstructured":"Jacobs JW, Stephens LD, Allen ES, et al. Epidemiological and clinical features, therapeutic strategies and outcomes in patients with hyperhaemolysis: a systematic review. Br J Haematol 2023;201:1025\u201332. doi: 10.1111\/bjh.18825.","DOI":"10.1111\/bjh.18825"}],"container-title":["Immunohematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/immunohematology-2025-019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T01:04:13Z","timestamp":1783904653000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/immunohematology-2025-019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":15,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,12,31]]},"published-print":{"date-parts":[[2025,12,1]]}},"alternative-id":["10.2478\/immunohematology-2025-019"],"URL":"https:\/\/doi.org\/10.2478\/immunohematology-2025-019","relation":{},"ISSN":["1930-3955"],"issn-type":[{"value":"1930-3955","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]}}}